Key result
Review highlights local drug delivery via implantable polymeric devices and DES biocompatibility and degradation.
This review summarizes the general aspects of local drug delivery by implantable polymeric devices, focusing on drug-eluting stents and their biocompatibility and degradation characteristics.
No change to current DES practice; extends polymer biocompatibility synthesis while leaving optimal degradation open for trials.
Implantable biomaterials mainly serve as physical support devices, carriers for bioactive molecules and guidance for tissue growth. For any application within or outside the cardiovascular area, biomaterials are subject to an extended set of requirements in order to establish safe application. These requirements mainly include acceptable biocompatibility and, if the material is to be degraded within the body, safe degradation characteristics. During degradation, biocompatible polymers are broken down into molecules that are metabolized and removed from the body via normal metabolic pathways. Major applications of these polymers include targeted drug delivery systems, resorbable sutures and orthopedic fixation devices. In the cardiovascular area they include biodegradable cardiovascular stents and drug-eluting stent (DES) coatings. This review focuses on general aspects of local drug delivery by implantable polymeric devices, with special emphasis on drug-eluting stents.
No takes yet. Share an insight, caveat, or question.
Commandeur et al. (2006) reported a review. Implantable polymeric devices and drug-eluting stents was evaluated. This review highlights the general aspects of local drug delivery by implantable polymeric devices, emphasizing the biocompatibility and degradation characteristics of drug-eluting stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: